Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience. (PubMed, Neurooncol Pract) - Sep 18, 2026 - "In this retrospective analysis of predominantly recurrent IDH-1-mutant glioma, ivosidenib was associated with longer PFS in lower-grade, non-enhancing tumors that received little or no prior anticancer treatment and less complex genomic profiles. These findings support a context-dependent benefit of IDH inhibition in recurrent disease."
Journal • Astrocytoma • Brain Cancer • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CDKN2A • CDKN2B • IDH1
|
|
Bryan J Neth; Caterina Giannini; Daniel H Lachance; Derek Johnson; Eric J Lehrer; Ganiru O Mathis; Ian F Parney; Jian L Campian; Joon H Uhm; Kristen L Drucker; Kurt Jaeckle; Maciej M Mrugala; Michael W Ruff; Robert B Jenkins; Sani H Kizilbash; Santiago Martínez Sosa; Sofia Rael; Sydney E Schultz; Taylor M Galloway; Terry C Burns; Ugur Sener; Wendy Sherman; William G Breen
|